Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (9985)	1/12/2004 6:21:01 PM
From: quidditch	Read Replies (1) \| Respond to of 52153

Peter, In the interest of following up on your post, do have a link for the conference agenda and presentations that you could post? I think I saw one earlier but lost track of it. Thank you. quid

To: Biomaven who wrote (9985)	1/12/2004 9:03:35 PM
From: Ian@SI	Respond to of 52153

Listened to the MLNM presentation. Audio only. Nothing much new - this morning's press releases were more informative and took less time.

To: Biomaven who wrote (9985)	1/12/2004 9:22:38 PM
From: manny t	Read Replies (2) \| Respond to of 52153

GORX, Any thoughts on the news and the potential for this stock: Dow Jones Business News Innovative Cos. Stock Up on Thyroid Drug-Making Patent Filing Monday January 12, 3:19 pm ET By Adam L. Freeman NEW YORK -- Innovative Companies Inc.'s shares climbed to a new 52-week high Monday after the company said it filed an application to patent a system it says stabilizes the manufacture of a thyroid drug a number of companies have had to recall. ADVERTISEMENT In a prepared statement, the Lago, Fla., health-product maker said its Belcher Pharmaceuticals unit filed a patent for a new process to make levothyoxine sodium. The announcement comes as Belcher prepares to begin commercial production of levothyroxine sodium for animals this month. The company also said it's working on an Abbreviated New Drug Application (News - Websites) to file with the Food and Drug Administration (News - Websites) , which would allow Belcher to manufacture and sell the human version of this drug. Abbott Laboratories (NYSE:ABT - News) is the leading maker of levothyoxine sodium, which it calls Syntrhoid. The company logged $489 million is sales from Synthroid in 2002. King Pharmaceuticals , Forest Laboratories and Jerome Stevens Pharmaceuticals Inc. also make the drug. Levothyroxine is a naturally occurring hormone produced by the thyroid, aiding in normal metabolism. The hormone is also used to treat goiter, the enlargement of the thyroid gland. At approximately 2:50 p.m. EST on the Nasdaq Stock Market (News - Websites) , shares of Innovative Companies traded up 22%, or $1.10, to $6.20. More than 382,000 shares have changed hands, compared with average daily volume of 63,000. Earlier, the stock hit a new 52-week high of $6.51. The previous high of $5.25 was set Dec. 30. NDC Health, a provider of information to the health industry, has estimated that combined 2002 retail sales for all levothyroxine sodium tablets totaled $ 1.1 billion. Innovative noted that because of "unique potency problems," millions of doses of this drug, from several manufacturers, have been recalled. In early 2003, King Pharmaceuticals recalled more than 84,000 bottles of its Levoxyl because of subpotency issues detected during stability testing, according to the FDA. And Forest Pharmaceuticals Inc. -- a unit of Forest Laboratories -- recalled more than 35,700 bottles of its Levothroid because the tablets contained trace levels of the solvent isophorone. Innovative Companies officials weren't immediately available for comment. -By Adam L. Freeman; Dow Jones Newswires; 201-938-5023 adam.freeman@dowjones.com

To: Biomaven who wrote (9985)	1/13/2004 12:50:14 AM
From: Spekulatius	Read Replies (1) \| Respond to of 52153

Interesting article in the print edition of the WSJ today (front page): " Researcher try to Cut New Path to the Pharmacy" As companies get gun shy, Nonprofits make drugs and conduct own trials. If someone here on this thread has access to the online edition he may post.

To: Biomaven who wrote (9985)	1/13/2004 1:50:54 PM
From: rkrw	Read Replies (1) \| Respond to of 52153

<<If anyone listens to any of the presentations, it would be great if you were to post your impressions. Doesn't have to be detailed - "nothing particularly new" or "must listen" would both be useful comments.>> I'll chip in with a contribution. REGN. * Deemphasizing axokine as presently formulated. Not sure the modest benefit will translate into enough commercial potential to justify a big spend. * Looking into less immunogenicic formulations. Why they didn't admit to the above two before, I don't know. * IL-1 trap. Claim they can push the dose higher and boost efficacy. I wonder if they worry about NVS taking a walk? * Driver VEGF trap. Up to 0.8 mg now in phase I dose escalation. Seeing responses. 2004 VEGF goals: Initiate 3-5 phase I combo studies with standard chemo. Initiate 2 single agent phase II studies Partner in Japan AMD systemic start trial early this year *AMD local start later in year

To: Biomaven who wrote (9985)	1/15/2004 6:34:59 PM
From: A.J. Mullen	Respond to of 52153

JP Morgan- General Impressions It's always crowded. The difference is in the mood, and this year it was up. Lot's of interest in the 20% of companies that were unlisted. But, having attended a lot of these conferences, the mood seems to be a lagging indicator - if not a contrarian one. Genomics was interesting in that Celera, Incyte and Myriad didn't present, while HGSI did - without mentioning the word. On the otherhand, two private companies, working in the area, Perlegen and Genomic Health, attracted great interest. The speaker and CEO for Genomic Health was applauded before he spoke. I can't recall another time that has happened. Ashley